Summary & Overview
HCPCS Level II J9320: Injection, streptozocin, 1 gram
HCPCS Level II code J9320 identifies a 1-gram injectable dose of streptozocin, a cytotoxic chemotherapy agent used in oncology treatment. As a defined drug administration code, J9320 matters nationally for accurate drug billing, claims adjudication, and aggregation of chemotherapy utilization data across payer systems. Proper coding supports drug cost tracking, clinical documentation alignment, and payment processing for infusion services.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service where streptozocin is administered, and the common clinical context for its use. The publication outlines billing benchmarks, payment policy considerations, and payer coverage patterns relevant to hospitals, oncology clinics, and infusion centers.
This resource provides: a clear definition of the service billed under J9320; the clinical and procedural setting for administration; and the types of benchmarks and policy updates readers can expect to review for national payer practices. Data not available in the input will be noted where applicable in the main publication.
Billing Code Overview
HCPCS Level II code J9320 describes an injection of streptozocin, 1 gram. This code represents a single-unit drug administration for the chemotherapeutic agent streptozocin used in oncology care.
Service Type: Injectable chemotherapeutic drug administration
Typical Site of Service: Hospital outpatient department, physician office clinic, or ambulatory infusion center
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with a history of metastatic pancreatic neuroendocrine tumor presents for systemic chemotherapy. The oncology team orders an intravenous antineoplastic agent, J9320 (injection, streptozocin, 1 gram). The patient arrives to an outpatient oncology infusion center. Nursing performs pre-infusion assessment including vitals, review of laboratory values (renal function, liver enzymes, complete blood count), and verification of informed consent. Streptozocin is reconstituted by pharmacy per institutional protocol and delivered to the infusion suite with the exact number of grams required. The infusion nurse confirms the drug, dose, and patient identity, establishes IV access, and administers the medication over the recommended infusion time with appropriate antiemetic prophylaxis and hydration as indicated. Post-infusion monitoring includes assessment for hypersensitivity, nausea, vomiting, and renal toxicity; documentation of lot number and amount administered is recorded in the medication administration record. Billing is submitted using HCPCS Level II code J9320 for each gram administered, with any applicable modifier to indicate payer-specific circumstances (for example JW for discarded drug portion). Typical sites of service include outpatient hospital infusion centers, physician office-based infusion suites, and freestanding oncology clinics. Typical patient scenario: adult oncology patient receiving systemic streptozocin for treatment of insulinoma or pancreatic neuroendocrine tumor, often combined with other agents or as part of a chemotherapy regimen, requiring IV administration and monitoring for renal and gastrointestinal adverse effects.
Coding Specifications
| Modifier | Description |
|---|